Rubicon Research Limited (BOM:544578)
India · Delayed Price · Currency is INR 1,725.25
-36.95 (-2.10%)
At close: Aug 21, 2026
Rubicon Research Revenue
Rubicon Research had revenue of 5.34B INR in the quarter ending June 30, 2026, with 51.59% growth. This brings the company's revenue in the last twelve months to 19.36B, up 46.65% year-over-year. In the fiscal year ending March 31, 2026, Rubicon Research had annual revenue of 17.54B with 36.57% growth.
Revenue (ttm)
19.36B
Revenue Growth
+46.65%
P/S Ratio
14.75
Revenue / Employee
15.01M
Employees
1,290
Market Cap
285.49B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 17.54B | 4.70B | 36.57% |
| Mar 31, 2025 | 12.84B | 4.30B | 50.40% |
| Mar 31, 2024 | 8.54B | 4.60B | 116.99% |
| Mar 31, 2023 | 3.94B | 799.52M | 25.50% |
| Mar 31, 2022 | 3.14B | -11.49M | -0.37% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Jubilant Pharmova | 86.08B |
| Abbott India | 70.04B |
| Granules India | 56.32B |
| J. B. Chemicals & Pharmaceuticals | 41.48B |
| GlaxoSmithKline Pharmaceuticals | 39.55B |
| Viyash Scientific | 35.75B |
| AstraZeneca Pharma India | 24.32B |
| Caplin Point Laboratories | 22.87B |
Rubicon Research News
- 8 days ago - Rubicon Research Transcript: Q1 26/27 - Transcripts
- 8 days ago - Rubicon Research Quarterly report: Q1 2027 - Filings
- 8 days ago - Rubicon Research Slides: Q1 2027 - Filings
- 3 months ago - Rubicon Research Annual report: Q4 2026 - Filings